| Patents for A61P 3 - Drugs for disorders of the metabolism (129,789) |
|---|
| 06/22/2005 | CN1628748A Blood fat reducing tablet and its preparation |
| 06/22/2005 | CN1628746A Externally applied medicine for treating diabetes |
| 06/22/2005 | CN1628725A Medicine for lowering blood fat |
| 06/22/2005 | CN1628701A Method for enzyme hydrolyzing ocean annulata species for pharmaceutical purpose and the product thereof |
| 06/22/2005 | CN1628693A Glossy ganoderma preparation containing main active substance of glossy ganoderma herb and preparing method thereof |
| 06/22/2005 | CN1628672A Serial compound iron/calcium nutritious element tonic and preparation method thereof |
| 06/22/2005 | CN1628669A Acipimox Dispersible tablet |
| 06/22/2005 | CN1628658A Mitiglinide/metformin hydrochloride oral compound antihypelipidemic preparation and preparation method thereof |
| 06/22/2005 | CN1628561A Combination for releasing lassitude and its preparation method and uses |
| 06/22/2005 | CN1207382C Lactob.plantarum ST-III strain and application in regulating blood fat |
| 06/22/2005 | CN1207294C Acetylenic ortho-sulfonamido and phosphinic acid amido bicyclic heteroaryl hydroxamic acids as TACE inhibitors |
| 06/22/2005 | CN1207055C Preparation method of cordyceps biological activity multivitamin intensifying agent |
| 06/22/2005 | CN1207048C Product for regulating blood-lipid and protecting liver and preparation process thereof |
| 06/22/2005 | CN1207044C Antilipemic antiatherosclerosis medicine composition and preparing method, application thereof |
| 06/22/2005 | CN1207043C Hypotensive and hypolipemic lowering tea |
| 06/22/2005 | CN1207036C Traditional Chinese medicine formula for treating hyperlipemia |
| 06/22/2005 | CN1207030C Natural bioreaction regulator with the functions of resisting cancer, resisting free radical damage and regulating immunity |
| 06/22/2005 | CN1207006C Process for preparing high-activity soft capsules of forest frog's oviduct fat |
| 06/22/2005 | CN1207003C Minerals and crystals collecting bag for health caring of human body |
| 06/22/2005 | CN1206985C Soluble L-calcium lactate preparation and preparing method |
| 06/22/2005 | CA2487107A1 Novel targets for obesity from skeletal muscle |
| 06/22/2005 | CA2487098A1 Novel targets for obesity from fat tissue |
| 06/21/2005 | US6909014 Intermediates for the synthesis of ether compounds |
| 06/21/2005 | US6908987 Comprises nucleotide sequences coding peroxisome proliferator activator receptor protein (PCG) for modulating thermogenesis in adipocytes and treating obesity |
| 06/21/2005 | US6908943 Use of γ-tocopherol and its oxidative metabolite LLU-α in the treatment of disease |
| 06/21/2005 | US6908942 Carbocyclic oxy amines such as 2,2-dimethyl-3-(4-fluorobenzyl) ether-4-methoxy-6-(4-methoxybenzyl)amino Benzopyran and libraries, used for prophylaxis of eating disorders induced by lipid peroxidation; antioxidants |
| 06/21/2005 | US6908938 Heterocyclic aromatic compounds useful as growth hormone secretagogues |
| 06/21/2005 | US6908935 Calcium receptor modulating agents |
| 06/21/2005 | US6908930 4-substituted 7-AZA-indolin-2-ones and their use as protein kinase inhibitors |
| 06/21/2005 | US6908927 Reduction physical cigarette smoking |
| 06/21/2005 | US6908922 Linear cyclic ureas |
| 06/21/2005 | US6908908 Biologically active 4H-benzo [1,4] oxazin-3-ones |
| 06/21/2005 | US6908905 N-substituted pyrazole-O-glycoside derivatives and therapeutic agent for diabetes containing the same |
| 06/21/2005 | US6908904 Pharmaceutical preparation and method for treatment of diabetes |
| 06/21/2005 | US6908897 At least one is a human or animal insulin analogue; coupled together with a diacid such as by reacting with suberic acid, bis(N-hydroxysuccinimidyl) ester |
| 06/21/2005 | US6908741 Receptor for advanced glycated endproducts (RAGE); solid phase synthesis; immunoassay |
| 06/21/2005 | US6908614 Anti-aging/menopause symptoms relief using ganoderma lucidum spores |
| 06/21/2005 | US6908609 Removing fluid from the intestinal tract of a host by directly delivering an effective amount of water-absorbent polymer to the intestinal tract |
| 06/21/2005 | CA2382387C Pharmaceutical formulations and use thereof in the prevention of stroke, diabetes and/or congestive heart failure |
| 06/21/2005 | CA2250372C 6-phenylpyridyl-2-amine derivatives |
| 06/19/2005 | CA2491278A1 Highly branched soluble glucose polymers |
| 06/17/2005 | CA2479432A1 Thiazole derivatives |
| 06/16/2005 | WO2005054213A1 Isoxazole derivative having agonistic activity against peroxisome proliferator-activated receptor |
| 06/16/2005 | WO2005053724A1 Compositions and method for treatment of steroid/nuclear receptor-mediated diseases |
| 06/16/2005 | WO2005053723A1 A composition comprising the extract of cucurbitaceae family plant or the purified extract isolated therefrom having anti-adipogenic and anti-obesity activity |
| 06/16/2005 | WO2005053675A1 A composition comprising the alcohol compound isolated from the extract of cucurbitaceae family plant having anti-adipogenic and anti-obesity activity |
| 06/16/2005 | WO2005032559A8 Nitric oxide donating derivatives for the treatment of cardiovascular disorders |
| 06/16/2005 | WO2005016255A3 Substituted tetrahydroquinolines, phenylacetic acids and benzoic acids as hepatocyte nuclear factor 4 (hnf-4 ) modulator compounds |
| 06/16/2005 | WO2005014029A3 Use of dg008, dg065, dg210 or dg 239 secreted protein products for preventing and treating pancreatic diseases, obesity or metabolic syndrome |
| 06/16/2005 | WO2005007658A3 Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto |
| 06/16/2005 | WO2004099782A3 Diagnostics and therapeutics for diseases associated with g-protein-coupled receptor gpr39 (gpr39) |
| 06/16/2005 | WO2004048565A9 Apoptosis-associated protein and use thereof |
| 06/16/2005 | WO2004047855A3 Proteins involved in the regulation of energy homeostasis |
| 06/16/2005 | WO2004046107A8 Indole derivatives as somatostatin agonists or antagonists |
| 06/16/2005 | WO2004037195A3 Treatment of diabetes |
| 06/16/2005 | WO1991001624A8 Use of calcium antagonists for treating scars |
| 06/16/2005 | US20050132448 Using streptomyces infected tubers as tools in diagnosing diabetes; macrolide antibiotic and onset of pancreatic disorders |
| 06/16/2005 | US20050132428 Cyclic amp phosphodiesterase 4d7 isoforms and methods of use |
| 06/16/2005 | US20050131242 2-substituted vitamin d derivatives |
| 06/16/2005 | US20050131237 Indole derivatives |
| 06/16/2005 | US20050131236 Central nervous ystem disorders; neurodegenerative disorders; muscle contraction; endocrine diseases |
| 06/16/2005 | US20050131161 Process for removing bile salts from a patient and alkylated compositions therefor |
| 06/16/2005 | US20050131060 Spirolaxine acts as active principle for treatment of those pathologies responding to activation of PPAR gamma receptor, such as acute malignant haemopathies. and Type 2 insulin-resistant diabetes |
| 06/16/2005 | US20050131052 Useful in treatment of type 2 diabetes, insulin resistance, syndrome X, hyperinsulinaemia, hyperglucagonaemia, cardiac ischaemia and obesity |
| 06/16/2005 | US20050131032 (Oxime)carbamoyl fatty acid amide hydrolase inhibitors |
| 06/16/2005 | US20050131027 Fine particle size pioglitazone |
| 06/16/2005 | US20050131016 Chemical compounds |
| 06/16/2005 | US20050131015 Heterocyclic amide derivatives as inhibitors of glycogen phoshorylase |
| 06/16/2005 | US20050131005 4-azasteroid derivatives as androgen receptor modulators |
| 06/16/2005 | US20050130998 Central nervous ystem diorders; Alzheimer's disease ; anticancer agents |
| 06/16/2005 | US20050130981 Compounds |
| 06/16/2005 | US20050130967 3-Substituted-4-pyrimidone derivatives |
| 06/16/2005 | US20050130963 Indole-amid derivatives which possess glycogen phosphorylase inhibitory activity |
| 06/16/2005 | US20050130953 Pharmacological uses of azetidine derivatives |
| 06/16/2005 | US20050130935 Combination of a beta-2-adrenoceptor agonists and an aminosugars and their use for the treatment immunomodulatory disorders |
| 06/16/2005 | US20050130933 As satiety-promoting ingredient dietary fiber as glucomannan and a gum, and a thermogenic ingredient of caffeine and/or a catechin-polyphenol such as epigallocatechin gallate (EGCG) |
| 06/16/2005 | US20050130929 For introduction of a disc prosthesis or implant; involves providing substance(s) beneficial to the intervertebral disc through a cannulated element |
| 06/16/2005 | US20050130927 For treating neoplasm, hypoproliferation, hyperproliferation, degenerative and neurodegenerative diseases, ischaemia, immune system disorder, infectious disease, or metabolic dysfunction |
| 06/16/2005 | US20050130916 Nucleic acid coding for the cgl1 polypeptide and diagnostic and therapeutic application of said nucleic acid and of the cgl1 polypeptide |
| 06/16/2005 | US20050130912 Compositions for the improvement of obesity |
| 06/16/2005 | US20050130903 Therapeutic agents and methods of use thereof for the modulation of angiogenesis |
| 06/16/2005 | US20050130902 Upregulate expression of a gene encoding an antioxidative anzyme, such as superoxide dismutase or catalase; neurodegenerative, cardiovascular, cerebral, disorders, trauma, injuries, burns, cancer |
| 06/16/2005 | US20050130891 Containing at least two of the following active substances A, B, C, wherein: A=at least one hormone stimulating the production of cAMP; B=at least one substance inhibiting the degradation of a cyclic nucleotide; C=at least one hormone stimulating the production of cGMP |
| 06/16/2005 | US20050130881 Single amino acid based compounds for counteracting effects of reactive oxygen species and free radicals |
| 06/16/2005 | US20050130880 zinc(II) organic complex with ligands selected from aminoalkylpyridines, bis-optically active amino acids, bisaminoalkylcarboxylic acids, oligopeptides, oligopseudopeptides, di-substituted aminocarboxylic acids, alpha - and beta -hydroxycarboxylic acids, vitamins, glutamine; insulin mimetics; less toxic; |
| 06/16/2005 | US20050130195 Functional molecule and process for producing the same |
| 06/16/2005 | US20050130145 polynucleotides which identify and encode human secreted proteins (SECP); expression vectors, host cells, antibodies, and agonists; drug screening |
| 06/16/2005 | US20050129788 Synergistic mixture of plant extracts; antidiabetic agents |
| 06/16/2005 | US20050129786 Topical composition having undifferentiated plant seed cells and method for using same |
| 06/16/2005 | US20050129784 Use of a chemically stabilized chlorite solution for inhibiting an antigen-specific immune response |
| 06/16/2005 | US20050129739 Production and use of a polar lipid-rich fraction containing omega-3 and/or omega-6 highly unsaturated fatty acids from microbes, genetically modified plant seeds and marine organisms |
| 06/16/2005 | US20050129663 Cellular therapy; for promoting axonal regeneration in the CNS, wound healing and treatment of myocardial infarction and spinal cord injury |
| 06/16/2005 | US20050129657 Interferon-alpha induced gene |
| 06/16/2005 | US20050129617 Contacting a T lymphocyte from the patient with a diagnostic epitope of an amino acid string including hydrophilic amino acids and one of Leucine, Methionine, Isoleucine, Phenylalanine, Alanine, Glycine, Valine, or Tryptophan |
| 06/16/2005 | DE202005003943U1 Oral composition for promoting wellbeing in humans, especially as an aid to weight loss, comprises at least two of basil, mint, sage, coriander, yarrow and tarragon |
| 06/16/2005 | CA2547887A1 Protein modifier production inhibitor |
| 06/16/2005 | CA2547791A1 Therapeutics use of pyridinium compounds to modulate naadp activity |
| 06/16/2005 | CA2547543A1 Use of pentadienoic acid derivatives for the treatment of hyperuricemia |
| 06/15/2005 | EP1541677A1 Novel proteins and use thereof |
| 06/15/2005 | EP1541672A1 Composition for promoting the proliferation of lactobacillus casei subsp. casei |